This text is a result of machine translation.
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
913 companies have been investigated by public funds since the second quarter, and the six top flow fund managers focus on the leaders of subdivided industries
Research
Consumer Staples, Technology, HealthcareWIA2020 | Rising Tech Stars 2020: Global & China's 100
Trautec Medical Raises Nearly CNY 200 Mn in Series A Financing Round
Trautec Medical, dedicated to developing and producing recombinant collagen-based biomaterials, will continue to focus on the innovation of biomaterials and strive to integrate resources from all sides.
Aug 12, 2022 06:12 PM
Preparation Developer Elite Pharmaceutical Nets Nearly CNY 100 Mn in Series B Round
This financing round will further promote the company's R&D and clinical trials and be used to construct new production bases. The completion of the new production base will significantly improve the application efficiency of the products independently developed by Elite and reduce the cost without reducing the capacity of the products.
Aug 12, 2022 05:56 PM
A number of enterprises on the science and innovation board are listed on the "white list" of key enterprises for operation guarantee and transfer
Aesthetic Medicine Company Tian Shi Wei Nets Tens of Millions of RMB in Series A Round
Soluble microneedle technology has received wide attention from the industry recently and is expected to be commercialized in aesthetic medicine. Tian Shi Wei gained capital preference for its R&D, mass production and quality control capabilities.
Aug 12, 2022 04:58 PM
Fengtai District of Beijing will lift the epidemic prevention zone of the whole region from now on.
Hong Kong stocks continued to rise in the anti epidemic sector, and Junshi biology rose nearly 17%
Envisioning the Future Mobility in China: the Status and Prospect of ICVs
Aug 12, 2022 06:08 PM